Last reviewed · How we verify
NCT04245280: PENG
Effectiveness of PENG Block Combined to LFCN Block on the Quality of Recovery After Total Hip Replacement
NA trial testing Ropivacaine 0.5% Injectable Solution in Total Hip Replacement Surgery in 74 participants. Completed in 31 July 2024.
31 July 2024
Quick facts
| Lead sponsor | Centre hospitalier de l'Université de Montréal (CHUM) |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 74 |
| Start date | 4 May 2021 |
| Primary completion | 31 July 2024 |
| Estimated completion | 31 July 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Ropivacaine 0.5% Injectable Solution — full drug profile →
- Saline Solution
Conditions studied
- Total Hip Replacement Surgery — all drugs for Total Hip Replacement Surgery →
- Postoperative Pain — all drugs for Postoperative Pain →
Sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Who can join
18 and older, any sex, with Total Hip Replacement Surgery or Postoperative Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of this study is to evaluate the effectiveness of the association of PENG and LFCN blocks on the quality of recovery 24 hours after total hip replacement surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04245280
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ropivacaine 0.5% Injectable Solution
Trials testing the same drug.
- NCT07180979 — PENG vs L-ESPB With S-ESPB for Analgesia in Total Hip Arthroplasty · Phase 4 · not yet recruiting
- NCT06379490 — Ultrasound-guided Infraclavicular Block With Lidocaine or Ropivacaine for Closed Reduction of Distal Radius Fractures · Phase 3 · completed
- NCT06381622 — Combining Lidocaine and Ropivacaine for an Infraclavicular Brachial Plexus Nerve Block · Phase 3 · completed
- NCT05767749 — Split Face Study of the Duration of Local Anesthetics · Phase 4 · completed
- NCT05024344 — ESP Block vs Control for Pain Control Following Percutaneous Nephrolithotomy · NA · recruiting
Other recruiting trials for Total Hip Replacement Surgery
Currently open trials in the same condition.
- NCT07226700 — Suzetrigine in Total Hip Arthroplasty · Phase 3 · recruiting
Other Centre hospitalier de l'Université de Montréal (CHUM) trials
Trials by the same sponsor.
- NCT06735638 — Outside the Cage (OTC) Robotic Esophagectomy · Phase 1 · not yet recruiting
- NCT07533253 — Rescue Distal Thrombectomy in Treatment for Persistent Distal Occlusions · NA · not yet recruiting
- NCT05225272 — Effectiveness of an Enhanced Recovery After Surgery Protocol in Patients Undergoing On-pump Cardiac Surgery · not yet recruiting
- NCT07497061 — Comparison of Two Surgical Techniques for the Treatment of Trigger Fingers: Longitudinal Opening Versus Complete A1 Pull · NA · not yet recruiting
- NCT07196410 — KAN-004 for Immune-Related Diarrhea or Colitis · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04245280 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre hospitalier de l'Université de Montréal (CHUM)
- Last refreshed: 6 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04245280.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing